MCQ Self Assessment Tests in Biopharmaceuticals – Biologics and Biosimilar Regulatory Affairs and Strategic Management
MCQ Tests on Biopharmaceuticals – Biologic and Biosimilar Regulatory Affairs and Strategic Management Career in Biopharmaceutical If you look today at global... Read More
Amgen and Array BioPharma’s preclinical license and collaboration agreement in inflammation
Amgen and Array BioPharma has entered into a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The... Read More
USFDA approval of Vosevi for Hepatitis C
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis... Read More
A close look into: AstraZeneca and Merck’s strategic oncology collaboration
AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered... Read More
Infinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Infinity Pharmaceuticals, Inc., an innovative biopharmaceutical company, has amended its license agreement with Takeda Oncology for IPI-549, Infinity’s potentially first-in-class immuno-oncology product... Read More
Panacea Biotec’s collaboration agreement with Bionpharma to develop 7 complex generics
Panacea Biotec has entered into joint collaboration for development, license, manufacturing, supply and sales of 7 complex generic pharmaceutical products with Bionpharma... Read More
Case Study: Pricing of Biosimilar – A present Trend in US market
Posted on25 Jul 2017
Comments0
We will look into a case study to understand present market trends as far as the pricing of the biosimilars are considered... Read More
Case Analysis : Japan’s Mitsubishi Tanabe’s acquisition of Israeli drug maker Neuroderm for $1.1 billion
Posted on25 Jul 2017
Comments0
Japan’s Mitsubishi Tanabe Pharma Corp has agreed to acquire Israeli drug maker Neuroderm for $1.1 billion in cash as part of a... Read More
Overview of PeptiDream, Kleo Pharma co-development licensing deal of immune-oncology products
PeptiDream, a Tokyo-based biopharmaceutical company and Kleo Pharmaceuticals, a New Haven-based company using its proprietary Antibody Recruiting Molecule (ARM) and Synthetic Antibody... Read More
Drug majors Mylan and Biocon’s biosimilar trastuzumab close to USFDA approval
Posted on17 Jul 2017
Comments0
Drug majors Mylan and Biocon on Friday said the US health regulator’s Oncologic Drugs Advisory Committee (ODAC) has recommended approval for their... Read More